Sandra Y. Vasey
Stockley Park
Uxbridge, United Kingdom
Uxbridge, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.
Journal: The New England journal of medicine
Published: June 15, 2026
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
Journal: Annals of hematology
Published: August 24, 2022
Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial.
Journal: JACC. CardioOncology
Published: November 01, 2021
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Journal: American journal of hematology
Published: September 14, 2021
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Journal: The New England journal of medicine
Published: June 30, 2021
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.
Journal: Journal of gastroenterology and hepatology
Published: February 25, 2015
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Journal: Gastroenterology
Published: April 18, 2013
Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia.
Journal: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
Published: March 16, 2013
Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP).
Journal: British journal of haematology
Published: July 20, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026